NIR-dye bridged human serum albumin reassemblies for effective photothermal therapy of tumor

Zhaoqing Shi, Miaomiao Luo, Qili Huang, Chendi Ding, Wenyan Wang, Yinglong Wu, Jingjing Luo, Chuchu Lin, Ting Chen, Xiaowei Zeng, Lin Mei (), Yanli Zhao () and Hongzhong Chen ()
Additional contact information
Zhaoqing Shi: Chinese Academy of Medical Sciences & Peking Union Medical College
Miaomiao Luo: Chinese Academy of Medical Sciences & Peking Union Medical College
Qili Huang: Sun Yat-sen University
Chendi Ding: Chinese Academy of Medical Sciences & Peking Union Medical College
Wenyan Wang: Sun Yat-sen University
Yinglong Wu: Nanyang Technological University
Jingjing Luo: Sun Yat-sen University
Chuchu Lin: Sun Yat-sen University
Ting Chen: Chinese Academy of Medical Sciences & Peking Union Medical College
Xiaowei Zeng: Sun Yat-sen University
Lin Mei: Chinese Academy of Medical Sciences & Peking Union Medical College
Yanli Zhao: Nanyang Technological University
Hongzhong Chen: Sun Yat-sen University

Nature Communications, 2023, vol. 14, issue 1, 1-13

Abstract: Abstract Human serum albumin (HSA) based drug delivery platforms that feature desirable biocompatibility and pharmacokinetic property are rapidly developed for tumor-targeted drug delivery. Even though various HSA-based platforms have been established, it is still of great significance to develop more efficient preparation technology to broaden the therapeutic applications of HSA-based nano-carriers. Here we report a bridging strategy that unfastens HSA to polypeptide chains and subsequently crosslinks these chains by a bridge-like molecule (BPY-Mal2) to afford the HSA reassemblies formulation (BPY@HSA) with enhanced loading capacity, endowing the BPY@HSA with uniformed size, high photothermal efficacy, and favorable therapeutic features. Both in vitro and in vivo studies demonstrate that the BPY@HSA presents higher delivery efficacy and more prominent photothermal therapeutic performance than that of the conventionally prepared formulation. The feasibility in preparation, stability, high photothermal conversion efficacy, and biocompatibility of BPY@HSA may facilitate it as an efficient photothermal agents (PTAs) for tumor photothermal therapy (PTT). This work provides a facile strategy to enhance the loading capacity of HSA-based crosslinking platforms in order to improve delivery efficacy and therapeutic effect.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-023-42399-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-42399-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-42399-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().